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Abstract
Levoﬂoxacin susceptibility testing was carried out for a total of 2539 Streptococcus pneumoniae isolates obtained from January 2001 to
February 2008 at the National Taiwan University Hospital (NTUH) and a further 228 pneumococcal isolates obtained from January
2004 to December 2006 at three other hospitals in different geographical areas in Taiwan. Levoﬂoxacin non-susceptible S. pneumoniae
isolates were subsequently analysed for serotype and molecular epidemiology. Rates of levoﬂoxacin non-susceptibility of
S. pneumoniae increased signiﬁcantly from 1.2% in 2001 to 4.2% in 2007 at NTUH. A total of 30 isolates of levoﬂoxacin non-susceptible
S. pneumoniae isolates (MIC ‡ 4 mg/L) were available for evaluation of serotype, antimicrobial susceptibility, nucleotide sequence of the
quinolone resistance-determining regions of parC, gyrA, parE and gyrB, reserpine effect on quinolone susceptibility and multilocus
sequence type. Among these isolates, seven (23.3%) were from children, and two (6.7%; one from a 3- and one from a 93-year-old
patient) were from blood. One levoﬂoxacin-resistant isolate (MIC = 8 mg/L) was recovered from a previously healthy child with bacte-
raemic necrotizing pneumonia complicated by empyema and a haemolytic-uraemic syndrome. All isolates except two had Ser79 and/or
Asp83 changes in ParC, and/or Ser81 or Glu85 changes in GyrA. An efﬂux phenotype concerning levoﬂoxacin was detected in only one
(3.3%) isolate. A novel clone (ST3642), genetically related to Spain9V-3 and belonging to serotype 11A, was identiﬁed. Dissemination of
clonal complexes related to Spain23F-1, Taiwan19F-14, Spain9V-3 and Taiwan23F-15 has contributed to levoﬂoxacin non-susceptibility
among these S. pneumoniae isolates from Taiwan.
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Introduction
Levoﬂoxacin, a newer ﬂuoroquinolone with increased activity
against Streptococcus pneumoniae, has been an effective anti-
microbial agent in treating adults with community-acquired
pneumonia. However, signiﬁcant increases in the incidence of
levoﬂoxacin resistance have been reported over the past
decade in some countries, such as Hong Kong, the USA,
Canada, Spain and South Africa [1–5].
Levoﬂoxacin is not approved for use in children. The
implementation of the pneumococcal 7-valent conjugate vac-
cine for children, beginning in 2000 in the USA, has success-
fully reduced the incidence of invasive pneumococcal disease
and acute otitis media caused by S. pneumoniae with vaccine
serotypes, and has decreased the spread of multidrug-resis-
tant S. pneumoniae [6–8]. Nevertheless, multidrug-resistant
S. pneumoniae with non-vaccine serotypes has emerged
[9,10]. These ﬁndings suggest the need for more prudent use
of ﬂuoroquinolones in order to maintain their effectiveness
as a defence against S. pneumoniae infection. This report
describes the serotypes, antimicrobial susceptibility and
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molecular epidemiology of levoﬂoxacin non-susceptible
S. pneumoniae isolates collected between 2001 and 2008 in
Taiwan.
Materials and Methods
Bacterial isolates
In order to analyse the trend of levoﬂoxacin non-susceptibility
among S. pneumoniae isolates, we collected non-duplicate (one
isolate per patient) clinical isolates recovered from various
clinical specimens (blood, pleural effusion, cerebrospinal ﬂuid,
ascites, sputum, and other respiratory secretions) of patients
treated at National Taiwan University Hospital (NTUH) from
2001 to 2008.These isolates were identiﬁed by conventional
biochemical methods [11]. Susceptibility results of S. pneumo-
niae were determined by the disk diffusion method [12].
In addition, during the period 2004–2006, a total of 228
S. pneumoniae isolates were prospectively collected from
three other hospitals in Taiwan: 36 from China Medical Col-
lege Hospital, Taichung; 18 from Buddist Tzu Chi General
Hospital, Hualien; and 174 from Chang-Gung Memorial Hos-
pital, Kaohsiung [13].
Antimicrobial susceptibility testing
Standard powders of ﬂuoroquinolones were obtained from
their manufacturers as follows: levoﬂoxacin (Daiichi Pharma-
ceuticals, Tokyo, Japan); oﬂoxacin (Daiichi Pharmaceuticals);
gatiﬂoxacin (Bristol-Myers Squibb, Princeton, NJ, USA);
moxiﬂoxacin and ciproﬂoxacin (Bayer Co., Leverkusen, Ger-
many); trovaﬂoxacin (Pﬁzer, New York, NY, USA); and gemi-
ﬂoxacin (GlaxoSmithKline, Greenford, UK).
The MICs of levoﬂoxacin were determined by the broth
microdilution method for levoﬂoxacin non-susceptible iso-
lates. The results were interpreted according to the guide-
lines established by the CLSI [12]. Streptococcus pneumoniae
ATCC 49619 was used as a quality control.
A total of 56 isolates, (50 isolates from the NTUH, 47
isolates from 2001–2007 and three isolates from 2008, and
six isolates from the three other hospitals) with levoﬂoxacin
MICs ‡ 4 mg/L were identiﬁed. Thirty isolates, including
24 isolates from the NTUH and six isolates from the
three other hospitals, were available for MIC determination
of oﬂoxacin, ciproﬂoxacin, gatiﬂoxacin, trovaﬂoxacin, moxi-
ﬂoxacin and gemiﬂoxacin by the broth microdilution method
(in-house panels) [11,12].
Reserpine efﬂux assay
The efﬂux phenotype was deﬁned as a fourfold or greater
reduction in the MICs of various quinolones tested in the
presence of reserpine (10 mg/L; Sigma, St Louis, MO, USA)
[14].
Serotyping
The serotypes of isolates were determined using the capsu-
lar swelling method (Quellung reaction). All antisera were
obtained from the Statens Seruminstitut (Copenhagen, Den-
mark).
PCR and DNA sequence analysis
Bacterial genomic DNA was prepared with the QIAGEN
Genomic DNA system (QIAGEN, Valencia, CA, USA). PCR
reactions to detect mutations in the quinolone resistance-
determining regions (QRDRs) were performed using
previously described primers [15].
Multilocus sequencing typing
Multilocus sequencing typing (MLST) was carried out as
previously described [16]. New MLST proﬁles were submit-
ted to the curator at http://spneumoniae.mlst.net for new ST
numbers. A clonal complex was deﬁned as previously
described [17].
Statistical analysis
Trends of rates of levoﬂoxacin non-susceptibility over time
were evaluated using the Cochran–Armitage Trend Test. A
p value < 0.05 was considered statistically signiﬁcant.
Results
Of the 2239 S. pneumoniae isolates collected at NTUH from
2001–2007, 47 (2.1%) were non-susceptible to levoﬂoxa-
cin (Fig. 1). There was a signiﬁcant increasing trend in
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FIG. 1. Trend of non-susceptibility to levoﬂoxacin among Streptococ-
cus pneumoniae isolates collected from 2001–2007 at National Tai-
wan University Hospital. *A signiﬁcant increasing trend (p <0.05)
from 2001–2007.
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levoﬂoxacin non-susceptible rates among S. pneumoniae iso-
lates at NTUH (p <0.05) (Fig. 1). A 3.5-fold increase in rates
from 1.2% in 2001 to 4.2% in 2007 was noted.
Among the 30 isolates of levoﬂoxacin non-susceptible
S. pneumoniae (MICs of ‡ 4 mg/L) available for study, 24
(80%) were collected from NTUH and seven (23.3%) were
recovered from children (Table 1). The majority of levoﬂox-
acin non-susceptible isolates (n = 28, 93.3%) were from
respiratory tract secretions. The mean age of these patients
was 62 years with a median of 77 years (range 3–93 years).
Two isolates (6.7%) were recovered from blood; one (isolate
3) from a 3-year-old boy, and the other (isolate 15) from a
93-year-old female patient. The previously healthy boy devel-
oped pneumococcal pneumonia complicated with necrotizing
pneumonia, empyema and haemolytic-uraemic syndrome. His
history was negative for day-care centre attendance and for
family members with a diagnosis of tuberculosis (TB). How-
ever, his history of antibiotic use could not be determined.
The adult patient had a history of chronic obstructive airway
disease and developed pneumococcal pneumonia with septic
shock.
The following seven serotypes were found among the lev-
oﬂoxacin non-susceptible isolates: 19F (n = 11, 36.7%), 23F
(n = 9, 30%), 14 (n = 4, 13.3%), 6B (n = 2, 6.7%), 9V (n = 1,
3.3%), 11A (n = 3, 10%).
Spread of international clones or clones related to inter-
national clones has been observed. Spain23F-1 (ST81) was the
largest clone, which included serotype 23F (n = 6) and sero-
type 19F (n = 4). Spain23F-1-related clones ST2891 (n = 2)
and ST83 (n = 1) were also found. Taiwan19F-14 (ST236) was
the second largest clone, which included serotype 19F
(n = 4) and serotype 14 (n = 1). Spain9V-3 (ST156)-related
clones ST3642 (n = 3), ST1569 (n = 1) and ST166 (n = 1)
constituted the third largest. ST 3642 was a novel clone con-
sisting of three isolates of serotype 11A. Among the isolates
with a levoﬂoxacin MIC of 64 mg/L, three (75%, 3/4)
belonged to ST3271 (double locus variant of Taiwan23F-
15(ST242)). Interestingly, each of these three isolates had a
different serotype (serotypes 23F, 19F and 14) and was
recovered in a different year (2003, 2006 and 2008). These
ﬁndings indicate that ST3271 isolates with high-level levoﬂox-
acin resistance circulated in the community.
Gemiﬂoxacin had the highest level of antipneumococcal
activity. The MICs of gemiﬂoxacin were 16- to 128-fold
lower than those of levoﬂoxacin. Only one of the levoﬂoxa-
cin non-susceptible isolates had a gemiﬂoxacin MIC which
exceeded 1 mg/L: isolate 18 with a gemiﬂoxacin MIC of
4 mg/L. According to the CLSI criteria, 60% (n = 18) of the
30 isolates were non-susceptible to gemiﬂoxacin and
trovaﬂoxacin, 63.3% (n = 19) were non-susceptible to
moxiﬂoxacin, 93.3% (n = 28) were non-susceptible to gatiﬂox-
acin and 100% (n = 30) were non-susceptible to oﬂoxacin.
Sequencing of the QRDRs of ParC, GyrA, ParE and GyrB
revealed seven types of amino acid substitution in ParC, four
types of amino acid substitution in GyrA, four types of amino
acid substitution in ParE and one type of amino acid substitu-
tion in GyrB (Table 1).
Most of the isolates with levoﬂoxacin MICs from 4 to
8 mg/L had amino acid changes involved in resistance, includ-
ing Ser79 or Asp83 alterations in ParC, or Ser81 or Glu85
alterations in GyrA. Isolates 16 and 29 were found not to
have a signiﬁcant amino acid change but a I460V polymor-
phism in ParE. Efﬂux phenotype was not detected in isolate
29. Isolate 16 had the same I460V polymorphism as isolate
29, but had an efﬂux phenotype. Most of the isolates with
levoﬂoxacin MICs from 16 to 64 mg/L had both Ser79 and/
or Asp83 changes in ParC, and Ser81 or Glu85 changes in
GyrA. Isolates 20, 21 and 22 only had S79Y changes in ParC
and the I460V polymorphism in ParE; these isolates had no
amino acid changes in GyrA and GyrB and lacked the efﬂux
phenotype.
Only some isolates of Spain23F-1 or Taiwan19F-14 shared
the identical amino acid changes or polymorphisms at the
QRDRs. Two isolates of Spain23F-1 carried K137N in ParC,
E85K in GyrA, and I460V, D435N in ParE. Three isolates of
Spain23F-1 carried S79F, K137N in ParC, S81F in GyrA,
I460V in ParE. Two isolates of Taiwan19F carried S79F in
ParC, and I460V in ParE. Amino acid changes or polymor-
phism in other isolates of Spain23F-1 or Taiwan19F-14 were
heterogeneous. By contrast, three isolates belonging to
ST3642 and three high-level levoﬂoxacin-resistant isolates
(MICs of 64 mg/L) belonging to ST3271 shared identical
amino acid changes and polymorphisms at the QRDRs.
An efﬂux phenotype concerning levoﬂoxacin was detected
in only one of the 30 levoﬂoxacin non-susceptible isolates.
Among the 30 levoﬂoxacin non-susceptible isolates, an efﬂux
mechanism contributing to ciproﬂoxacin resistance was
detected in 14 isolates, to gemiﬂoxacin resistance in three
isolates, and to moxiﬂoxacin resistance in one isolate.
Discussion
Taiwan is a country with a high prevalence of b-lactam and
macrolide-resistant S. pneumoniae [11]. Nevertheless, the
most recent previous studies from Taiwan found the overall
prevalence rate of levoﬂoxacin resistance in S. pneumoniae to
be only c. 2% [11,13]. During the 8-year period of the
present study, levoﬂoxacin non-susceptibility among S. pneu-
moniae isolates increased over time at NTUH, and thus a
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total of 30 isolates not susceptible to levoﬂoxacin were col-
lected for analysis. Reported risk factors for levoﬂoxacin
resistance were nosocomial infection, age in conjunction with
‡ 75 years chronic obstructive airway diseases, residence
in a nursing home, and prior ﬂuoroquinolone treatment
[18]. In the study, we identiﬁed an invasive isolate of
levoﬂoxacin-resistant S. pneumoniae from a previously healthy
child. Levoﬂoxacin resistance was rarely seen in children
because ﬂuoroquinolones are not recommended for use in
paediatric patients. There have been few reports on invasive
disease caused by levoﬂoxacin non-susceptible S. pneumoniae
in children [5,19,20]. Most cases of invasive disease caused
by levoﬂoxacin non-susceptible S. pneumoniae have been
in human immunodeﬁciency virus-seropositive children
with a history of TB treatment (some patients received ﬂu-
oroquinolones in the regimen), who usually had associated
nosocomial infections [5]. Taiwan is an area of high disease
burden, with a high incidence of drug-resistant TB [21].
Whether the use of ﬂuoroquinolones in the treatment of TB
in adults has increased the potential for spread of levoﬂoxa-
cin non-susceptible S. pneumoniae in children remains to be
studied.
Reports on the clonal spread of ﬂuoroquinolone-resistant
S. pneumoniae are not as abundant as those on penicillin-
resistant strains. Clonal dissemination attributable to ﬂuor-
oquinolone resistance has been reported in Hong Kong, the
USA and Spain [1,3,4]. In Canada and Korea, the genetic
relationship among ﬂuoroquinolone-resistant pneumococcal
isolates was heterogeneous [14,22], which indicated that ﬂu-
oroquinolone resistance arose via independent mutations. In
Spain, ﬂuoroquinolone resistance was found to have been
acquired by pre-existing clones through point mutation or
recombination with viridians streptococci [23]. In this study,
we found that dissemination of the international clones
Spain23F-1, Taiwan19F-14 and Taiwan23F-15 contributed to
levoﬂoxacin resistance in S. pneumoniae in Taiwan. The hetero-
geneity of amino acid substitutions in the QRDRs among iso-
lates belonging to Spain23F-1 and Taiwan19F-14 clones suggests
that these organisms disseminate not only by clonal spread but
also by independent selection due to antimicrobial pressure.
Interestingly, dissemination of clonal complexes related to
Spain23F-1, Taiwan19F-14 and Taiwan23F-15 was also responsi-
ble for the spread of high b-lactam resistance in Taiwan [13].
These international clones might have some biological advan-
tage that enables them to build up various antimicrobial resis-
tances. On the other hand, we found that ST3271 (double
locus variant of Taiwan23F-15), with high-level resistant strains,
circulated in the community in different years but were not
increasing in frequency; these appear to have more of a ran-
dom occurrence than clonal dissemination.
Fluoroquinolone resistance in S. pneumoniae is mediated
by mutations in the QRDRs of DNA gyrase and/or topo-
isomerase IV, or by decreasing intracellular drug accumula-
tion through active efﬂux [24]. Decreased ﬂuoroquinolone
susceptibility in S. pneumoniae occurs in a stepwise fashion,
which is also dependent on the selecting agents [25]. Gener-
ally, amino acid changes at ParC/S79 or GyrA/S81 confer ﬂu-
oroquinolone resistance, whereas amino acid changes at
ParC/K137 and ParE/I460 do not [26]. In the present study,
all but two of the isolates had Ser79 and/or Asp83 altera-
tions in ParC, and/or Ser81 or Glu85 alterations in GyrA.
The efﬂux pump had the greatest effect on ciproﬂoxacin
MICs. Reserpine-inhibited efﬂux was found not only in
isolates with low-level ciproﬂoxacin resistance but also in iso-
lates with high-level ciproﬂoxacin resistance. Isolate 29 had a
levoﬂoxacin MIC of 4 mg/L, but only one amino acid alter-
ation was found: I460V polymorphism in parE. I460V in parE
has not been found to contribute to ﬂuoroquinolone resis-
tance in previous studies [26]. The MICs of levoﬂoxacin in
isolates 20, 21 and 22 were the same as in isolate 19.
However, isolate 19 had an additional amino acid change of
S81F in GyrA, which has been shown to contribute to
increased levoﬂoxacin MICs in numerous previous studies [26].
Based on the above two observations of isolates with increased
levoﬂoxacin MICs lacking resistance-associated mutations, we
hypothesize that genes other than topoisomerase genes may
be involved in levoﬂoxacin resistance in pneumococci.
Four isolates with high-level levoﬂoxacin resistance
(MIC = 64 mg/L) in this study had both Ser79 and Asp83
changes in ParC and Ser81 or Glu85 changes in GyrA. In a
previous study, E85K in GyrA was found only in S. pneumo-
niae isolates with high-level ciproﬂoxacin resistance [27].
With regard to levoﬂoxacin resistance, isolate 18 harbouring
E85K in GyrA had high-level levoﬂoxacin resistance. How-
ever, isolates 1 and 2 also had E85K in GyrA but the MICs
of levoﬂoxacin (8 mg/L) revealed only low-level resistance.
Our results indicate that E85K in GyrA contributes to high-
level levoﬂoxacin resistance in situations where there is a
relevant previous mutation in ParC.
This study documents a signiﬁcant increasing trend of
levoﬂoxacin non-susceptibility among S. pneumoniae isolates
at NTUH. These results may not represent the situation in
the whole of Taiwan however, and continued surveillance of
levoﬂoxacin resistance in S. pneumoniae is needed.
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